On March 26, 2025, the FDA approved Fresenius Kabi’s denosumab biosimilars, CONEXXENCE® (denosumab-bnht) and BOMYNTRA® (denosumab-bnht), ...
"This expansion gives us the opportunity to help even more people in our community, and we are honored to do so," the ...
The primary driver behind last 12 months revenue was the Fresenius Helios segment contributing a total revenue of €12.7b (58% of total revenue). Notably, cost of sales worth €16.5b amounted to 75% of ...
The FDA has approved two new denosumab biosimilars that are interchangeable with the reference medications Prolia and Xgeva, ...
LAKE ZURICH, IL, USA I March 27, 2025 I Fresenius announced that the Biologics License Application (BLA) for the denosumab biosimilars Conexxence® ...
Zacks Research boosted their Q1 2025 EPS estimates for shares of Fresenius Medical Care in a report released on Tuesday, ...
Denosumab-bnht is expected to launch in the US in June 2025 per an agreement with the reference product’s manufacturer, Amgen ...
JD.com, City Office REIT, Fresenius Medical Care, Itron and Enersys have been highlighted in this Screen of The Week article.
In a report released today, Graham Doyle from UBS maintained a Buy rating on Fresenius SE & Co. KGaA (0OO9 – Research Report), with a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback